dc.contributor.author | Curran, Desmond | |
dc.contributor.author | Pozzo, Carmelo | |
dc.contributor.author | Zaluski, Jerzy | |
dc.contributor.author | Dank, Magdalena | |
dc.contributor.author | Barone, Carlo | |
dc.contributor.author | Valvere, Vahur | |
dc.contributor.author | Yalcin, Suayib | |
dc.contributor.author | Peschel, Christian | |
dc.contributor.author | Wenczl, Miklós | |
dc.contributor.author | Goker, Erdem | |
dc.contributor.author | Bugat, Roland | |
dc.date.accessioned | 2019-12-10T11:20:18Z | |
dc.date.available | 2019-12-10T11:20:18Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 0962-9343 | |
dc.identifier.uri | https://doi.org/10.1007/s11136-009-9493-z | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724642/ | |
dc.identifier.uri | http://hdl.handle.net/11655/15301 | |
dc.description.abstract | Purpose The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented. Methods Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling. Results A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm. Conclusion There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer. | |
dc.relation.isversionof | 10.1007/s11136-009-9493-z | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | Quality Of Life of Palliative Chemotherapy Naive Patients with Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction Treated with Irinotecan Combined with 5-Fluorouracil And Folinic Acid: Results of A Randomised Phase Iii Trial | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Quality of Life Research | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 18 | |
dc.identifier.issue | 7 | |
dc.identifier.startpage | 853 | |
dc.identifier.endpage | 861 | |
dc.description.index | PubMed | |
dc.description.index | WoS | |
dc.description.index | Scopus | |